Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing

Elisa Ebrille, Tomas Konecny, Dana Konecny, Radim Spacek, Paul Jones, Pavel Ambroz, Christopher V. Desimone, Brian D. Powell, David L. Hayes, Paul Andrew Friedman, Samuel J Asirvatham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. Patients and Methods The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). Results A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75%); level II, 226/1231 (18%); level III, 60/1231 (5%); and level IV, 21/1231 (2%). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). Conclusion In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalMayo Clinic Proceedings
Volume90
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Implantable Defibrillators
Shock
Databases
Therapeutics
Cardiac Arrhythmias
Cohort Studies
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing. / Ebrille, Elisa; Konecny, Tomas; Konecny, Dana; Spacek, Radim; Jones, Paul; Ambroz, Pavel; Desimone, Christopher V.; Powell, Brian D.; Hayes, David L.; Friedman, Paul Andrew; Asirvatham, Samuel J.

In: Mayo Clinic Proceedings, Vol. 90, No. 2, 01.02.2015, p. 202-208.

Research output: Contribution to journalArticle

Ebrille, E, Konecny, T, Konecny, D, Spacek, R, Jones, P, Ambroz, P, Desimone, CV, Powell, BD, Hayes, DL, Friedman, PA & Asirvatham, SJ 2015, 'Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing', Mayo Clinic Proceedings, vol. 90, no. 2, pp. 202-208. https://doi.org/10.1016/j.mayocp.2014.11.011
Ebrille, Elisa ; Konecny, Tomas ; Konecny, Dana ; Spacek, Radim ; Jones, Paul ; Ambroz, Pavel ; Desimone, Christopher V. ; Powell, Brian D. ; Hayes, David L. ; Friedman, Paul Andrew ; Asirvatham, Samuel J. / Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing. In: Mayo Clinic Proceedings. 2015 ; Vol. 90, No. 2. pp. 202-208.
@article{1639cdf6ba4740e6bfb3959f6fee945f,
title = "Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing",
abstract = "Objective To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. Patients and Methods The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). Results A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75{\%}); level II, 226/1231 (18{\%}); level III, 60/1231 (5{\%}); and level IV, 21/1231 (2{\%}). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). Conclusion In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.",
author = "Elisa Ebrille and Tomas Konecny and Dana Konecny and Radim Spacek and Paul Jones and Pavel Ambroz and Desimone, {Christopher V.} and Powell, {Brian D.} and Hayes, {David L.} and Friedman, {Paul Andrew} and Asirvatham, {Samuel J}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.mayocp.2014.11.011",
language = "English (US)",
volume = "90",
pages = "202--208",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing

AU - Ebrille, Elisa

AU - Konecny, Tomas

AU - Konecny, Dana

AU - Spacek, Radim

AU - Jones, Paul

AU - Ambroz, Pavel

AU - Desimone, Christopher V.

AU - Powell, Brian D.

AU - Hayes, David L.

AU - Friedman, Paul Andrew

AU - Asirvatham, Samuel J

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. Patients and Methods The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). Results A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75%); level II, 226/1231 (18%); level III, 60/1231 (5%); and level IV, 21/1231 (2%). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). Conclusion In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.

AB - Objective To investigate a potential relationship between implantable cardioverter defibrillator (ICD) therapies and daily geomagnetic activity (GMA) recorded in a large database. Patients and Methods The ALTITUDE database, derived from the Boston Scientific LATITUDE remote monitoring system, was retrospectively analyzed for the frequency of ICD therapies. Daily GMA was expressed as the planetary K-index and the integrated A-index and was graded as levels I (quiet), II (unsettled), III (active), and IV (storm). Results A daily mean ± SD of 59,468±11,397 patients were monitored between January 1, 2009, and May 15, 2012. The distribution of days according to GMA was as follows: level I, 924/1231 (75%); level II, 226/1231 (18%); level III, 60/1231 (5%); and level IV, 21/1231 (2%). The daily mean ± SD numbers of ICD shocks received per 1000 active patients in the database were 1.29±0.47, 1.17±0.46, 1.03±0.37, and 0.94±0.29 on level I, II, III, and IV days, respectively; the daily mean ± SD sums of shocks and antitachycardia pacing therapies were 9.29±2.86, 8.46±2.45, 7.92±1.80, and 7.83±2.28 on quiet, unsettled, active, and storm days, respectively. A significant inverse relationship between GMA and frequency of ICD therapies was identified, with the most pronounced difference between level I and level IV days (P<.001 for shocks; P=.008 for shocks + antitachycardia pacing). Conclusion In a large-scale cohort analysis, ICD therapies were delivered less frequently on days of higher GMA, confirming the previous pilot data and suggesting that higher GMA does not pose an increased risk of arrhythmias using ICD therapies as a surrogate marker. Further studies are needed to gain an in-depth understanding of the underlying mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84961290246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961290246&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.11.011

DO - 10.1016/j.mayocp.2014.11.011

M3 - Article

VL - 90

SP - 202

EP - 208

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -